Gene Therapy Safety
More than 6,000 patients had received AAV-based gene therapy without serious harm reported in the article context. The rare case does not change the basic preference for AAV vectors in gene therapy. The case suggests that comparatively low…
1 sources - 4 claims
More than 6,000 patients had received AAV-based gene therapy without serious harm reported in the article context. The rare case does not change the basic preference for AAV vectors in gene therapy. The case suggests that comparatively low-risk gene therapy platforms can still carry residual risks. The event has safety implications for patients who receive gene therapy.